Bridgeway Capital Management, LLC Lineage Cell Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

$4.38 Billion
Q3 2025

A detailed history of Bridgeway Capital Management, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 221,000 shares of LCTX stock, worth $419,900. This represents 0.01% of its overall portfolio holdings.

Number of Shares

221,000

Previous 150,000 47.33%

Holding current value

$419,900

Previous $136,000 180.88%

% of portfolio

0.01%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.87 - $1.79 $61,770 - $127,090	71,000 Added 47.33%	221,000 $382,000
Q2 2025 Aug 14, 2025	SELL	$0.39 - $1.13 $6,981 - $20,226	-17,900 Reduced 10.66%	150,000 $136,000
Q1 2025 May 15, 2025	SELL	$0.45 - $0.72 $112,500 - $180,000	-250,000 Reduced 59.82%	167,900 $75,000
Q4 2024 Feb 14, 2025	SELL	$0.5 - $0.95 $169,433 - $321,922	-338,866 Reduced 44.78%	417,900 $208,000
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.12 $60,000 - $84,000	75,000 Added 11.0%	756,766 $688,000

Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $86,000 - $148,000	-100,000 Reduced 12.79%	681,766 $1.01 Million
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $550,902 - $810,150	540,100 Added 223.49%	781,766 $914,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $172,550 - $270,279	-152,700 Reduced 38.72%	241,666 $273,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $425,264 - $611,317	379,700 Added 2588.98%	394,366 $623,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $245,146 - $502,448	-202,600 Reduced 93.25%	14,666 $23,000
Q4 2021 Feb 14, 2022	SELL	$1.84 - $2.68 $20,240 - $29,480	-11,000 Reduced 4.82%	217,266 $532,000
Q3 2021 Nov 15, 2021	SELL	$2.26 - $2.86 $832,043 - $1.05 Million	-368,161 Reduced 61.73%	228,266 $575,000
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $101,365 - $140,136	-46,712 Reduced 7.26%	596,427 $1.7 Million
Q1 2021 May 17, 2021	SELL	$1.77 - $3.1 $66,729 - $116,870	-37,700 Reduced 5.54%	643,139 $1.51 Million
Q4 2020 Feb 16, 2021	BUY	$0.95 - $1.83 $91,485 - $176,229	96,300 Added 16.47%	680,839 $1.2 Million
Q3 2020 Nov 16, 2020	BUY	$0.75 - $1.09 $94,859 - $137,862	126,479 Added 27.61%	584,539 $547,000
Q2 2020 Aug 14, 2020	SELL	$0.71 - $1.18 $50,395 - $83,755	-70,979 Reduced 13.42%	458,060 $399,000
Q3 2019 Nov 14, 2019	BUY	$0.85 - $1.24 $449,683 - $656,008	529,039 New	529,039 $518,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Account

Bridgeway Capital Management, LLC Lineage Cell Therapeutics, Inc. Transaction History